Transcription of the E6-E7 genes of human papillomavirus type 11 (HPV-11), HPV-16 and HPV-18 is specific to epithelial cells. This mechanism originates from synergism between different transcription factors such as AP-1, NFI and Sp1, which occur in many different cell types, but whose activity is biased in favour of epithelial cells. In this study, the transcriptional regulation of 14 different papillomavirus types in the absence of the viral E2 transcription factor was compared. Genital HPV types, including high-risk, low-risk and common wart-associated HPVs, were found to have strong epithelial specific enhancers, irrespective of mucosal or skin target cell and pathology. Skin specific non-genital HPVs, like HPV-1 and HPV-8, as well as bovine papillomavirus type 4 (BPV-4), had much lower enhancer activity. Contiguous genomic segments including the enhancer and the E6 promoter of genital as well as non-genital papillomaviruses generally had very low transcriptional activities, presumably due to silencers between enhancer and promoter sequences. This generalization applies to all cell types tested in spite of significant quantitative differences between the cervical carcinoma-derived cell line HeLa, the skin-derived cell line HaCat, undifferentiated and differentiated primary keratinocytes. The only enhancer with activity in fibroblasts was identified in BPV-1, apparently a reflection of the broader target cell specificity of this virus. The low transcriptional activity of papillomaviruses most likely reflects the low gene expression required during most or even all parts of the life-cycle of these viruses.
Introduction
Transcription of papillomaviruses (PVs) is regulated by cisresponsive elements located in the long control regions (LCRs). The LCRs make up 5 to 10 % of the circular DNA genomes, as their sizes range from 400 to 900 bp depending on the virus type. These LCRs contain between four and 12 binding sites for viral E2 transcription factors, numerous binding sites for several other cellular transcription factors, one to four promoters, and a binding site for the E1 replication protein (for reviews see Howley, 1996) . More than 110 PV types are known (Bernard & Chan, 1997) ; of these, eight PV types are used as models for transcription research. These are the genital human PV (HPV) types HPV-11, HPV-16, HPV-18 and HPV-31 (Cripe et al., 1987 ; Gloss et al., 1987 ; Dollard et al., 1993 ; Butz & Hoppe-Seyler, 1993 ; Kyo et al., 1995) , and the more taxonomically distant Epidermodysplasia Author for correspondence : Hans-Ulrich Bernard.
Fax j65 779 1117. e-mail mcbhub!mcbsgs1.imcb.nus.edu.sg verruciformis-associated HPV-8 (Horn et al., 1993) , the cottontail rabbit PV (Wettstein et al., 1987) and the bovine PVs BPV-1 (Spalholz et al., 1985) and BPV-4 (Jackson & Campo, 1995) .
Transcriptional research has identified properties specific for some PV types, but many presumed differences may have merely historical origins. For example, BPV-1 became the model system for elucidating the transcription activation function of E2 proteins (Spalholz et al., 1985) , while genital HPVs are a model for E2 proteins being repressors (Dostatni et al., 1991 ; Tan et al., 1994) . While in most PV types, the E6 gene promoter is the principal source of transcripts, its activity is barely detectable in HPV-8. In this virus, a late promoter predominates, which has not been detected in genital HPVs (Horn et al., 1993 ; Stubenrauch et al., 1996) .
A fascinating regulatory property of PVs involves epithelial specific enhancers, which have been described only in some genital HPVs. ' Epithelial specificity ' refers to the capacity to strongly stimulate homologous and heterologous promoters in cell lines expressing epithelial markers such as certain keratin genes. This activity is similar in cell lines that are derived from cutaneous, squamous mucosal and simple mucosal epithelia. The same constructs demonstrate very little activity in endothelial or hepatic cells in spite of their keratin expression, and no activity in cells of other differentiation types, such as fibroblasts or cells of lymphoid lineage (Cripe et al., 1987 ; Gloss et al., 1987 ; Chong et al., 1991) .
Nearly 20 different transcription factors have been described as binding the LCRs of PVs. Mostly, these factors initially had been described from genes not specific to epithelial cells, namely AP-1, cEBP, steroid receptors, NFI, Oct-1, Sp1, TEF-1, TEF-2 and YY1 (for a review see . Additional, presumably novel, factors have been proposed as some gel shifts could not be explained by reference to known factors (Mack & Laimins, 1991 ; Kyo et al., 1995 ; Sibbet et al., 1995) . A major complication of all these studies has been the analysis of a complex multifactorial system by scrutinizing each factor in isolation. There are conflicting opinions about the specific contribution of each factor, but there is agreement that (i) no factor that activates the enhancers of genital HPVs exists only in epithelial cells, and (ii) that epithelial specificity should reside in factors that occur ubiquitously. Among these ubiquitous factors, AP-1 and NFI have attracted much attention as their binding motifs are easy to identify and occur frequently in the enhancers of all genital HPVs and many other PVs.
AP-1 binds two to three binding sites in HPV-11, HPV-16, HPV-18 and HPV-31, and mutations suggest that these sites make the greatest contribution to enhancer strength (GarciaCarranca et al., 1988 ; Gloss et al., 1989 a ; Dollard et al., 1993 ; Butz & Hoppe-Seyler, 1993 ; Kyo et al., 1995) . AP-1, a dimer of functionally differing Jun and Fos subunits, contributes to epithelial specificity as the expression of the jun and fos family genes differs between epithelial cells and fibroblasts (Thierry et al., 1992 ; Offord et al., 1993 ; Lu et al., 1994 ; Welter & Eckert, 1995 ; Jang et al., 1996) . Multiple AP-1 sites alone, however, do not establish a strong enhancer, although such constructs are more active in epithelial cells than in fibroblasts (Chong et al., 1991) . The AP-1 sites of all genital HPVs are surrounded by a cluster of half-palindromic NFI binding sites. Mutations and binding site competition have confirmed a contribution of NFI to the cell type specificity of HPV enhancers (Gloss et al., 1989 b ; Chong et al., 1991 ; Dollard et al., 1993) . Epithelial specific activation by NFI originates from the competition between the activator NFI-C and the repressor NFI-X, which are differentially expressed in epithelial and non-epithelial cells (Apt et al., 1993 (Apt et al., , 1994 . NFI depends both on the context of ciselements and on the cell type, as an NFI contribution was not observed in some mutants and some specific cellular environments (Butz et al., 1993 ; Zhao et al., 1997) .
The research reported here had three objectives. First, we wished to test whether clusters of NFI and AP-1 motifs in the LCRs of HPVs predict the location of enhancers. Secondly, we wished to examine whether epithelial specific enhancers were restricted to genital HPVs, or whether they would also be found in unrelated PV types. Thirdly, we hoped to observe whether the transcriptional properties of these LCRs correlate with the phylogenetic relationship of PVs or rather with their biology and pathology. For example, we wondered whether the enhancers of high-risk HPVs (HPV-16, HPV-18) would be stronger than those of low-risk HPVs, such as HPV-6 and HPV-11, considering their role in regulating viral oncogene expression. In addition, we asked whether the enhancer dictates the tropism of some viruses (HPV-16, HPV-18) for mucosal epithelia, and that of other viruses (e.g. HPV-1, HPV-2, HPV-4, HPV-8) for the skin. To reduce the complications posed by the study of multivariant systems, we explicitly excluded from this research the PV E2 transcription factor and its synergism and antagonism with cellular proteins.
Methods
Construction of plasmids. To examine the LCR of different PV types, we followed two strategies. In the first approach, we linked potential enhancer segments of 14 different PV types to the heterologous HPV-16 promoter in the chloramphenicol acetyltransferase (CAT) expression vector p80 (O'Connor et al., 1996) . This vector contains a segment of the HPV-16 p97 promoter with a TATA box and an Sp1 binding site, which is conserved among all genital HPVs (Gloss & Bernard, 1990 ; Hoppe-Seyler & Butz, 1992 ; Dong et al., 1994) but may be absent from the E6 promoters of unrelated PVs. Transcription from these constructs thus relies on the synergism between enhancer-bound factors and this Sp1 site. In the second approach, we inserted the complete LCR in front of the CAT gene in the promoter test vector pBLCAT3 (Luckow & Schu$ tz, 1987) . In these constructs, a potential enhancer would activate the homologous E6 promoter sequences. All LCR segments were generated by PCR with primers that generated a HindIII site or a BglII site (5h and 3h side of the amplified fragment, respectively, as listed in Table 1 ). The PCR reactions, purification of PCR products, restriction digestion, ligation into the HindIII-BglII cut vectors and confirmation of the complete sequence by DNA sequencing followed standard procedures. Table 1 lists the oligonucleotides used to amplify genomic fragments of each virus and identifies their genomic positions. These numbers identify each fragment by comparison against published data (Myers et al., 1997) , and Fig. 1 symbolizes the cloned fragments. Vectors where CAT gene expression occurred in pBLCAT3 from the contiguous enhancer-promoter segments were termed pHPV-Xpe (' pe ' fragments in Fig. 1) , and vectors where CAT expression depended on the HPV-16 promoter in p80 were termed pHPV-Xe (' e ' fragments in Fig. 1 , X refers to the virus type). In the case of BPV-1, BPV-4, HPV-1 and HPV-8, we also cloned the whole ' pe ' fragment into p80 and termed these vectors pHPV-XLe.
Cell culture, transfection and CAT assays. To measure HPV transcription, we used HeLa, HaCat and MRHF cells (Apt et al., 1993 ; Chong et al., 1991 ; Cripe et al., 1987) and primary human foreskin keratinocytes (Cascade Biologics). HeLa cells are derived from a cervical carcinoma and, as they express some genes from endogenous HPV-18 genomes, are considered a typical host cell of genital HPVs. HaCat is a spontaneously transformed human keratinocyte cell line, which maintains the capacity to differentiate and should therefore represent a transcriptional environment similar to skin (Boukamp et al., 1988) . MRHF cells are immortalized human fibroblasts (Apt et al., 1993) . A total of 10( cells were transfected with 10 µg of reporter vector by electroporation (HeLa, MRHF) or lipofectamine (Gibco-BRL) (HaCat, primary keratinocytes), Table 1 . Oligonucleotides for the PCR amplification and cloning of PV LCR fragments with potential enhancer activity
The oligonucleotides identify the 5h and the 3h ends of LCR segments, whose exact genomic position (Myers et al., 1997) is indicated. The first eight nucleotides contain artificial HindIII or BglII restriction sites to allow the 5h to 3h oriented cloning into p80 and pBLCAT3 for enhancer and enhancer-promoter assays, respectively. For amplification of enhancer-promoter segments, the promoter oligonucleotide (indicated by ' Pr') was combined with the same 5h oligonucleotide that was used for enhancer cloning, with the exception of HPV-1, where a different 5h oligonucleotide (N HPV-1 5h) was combined with the oligonucleotide N HPV-1Pr.3h. The LCR of BPV-1, contiguously cloned using BPV-1 5h and BPV-1 3h, was subdivided into three segments, by combining BPV-1 5h with BPV-1 A 3h, BPV-1 B 5h with BPV-1 C 3h, and BPV-1 D 5h with BPV-1 Pr.3h. For a schematic representation of all clones, see Fig. 1 harvested after 48 h and CAT expression was assayed by standard protocols. Culture, differentiation by suspension in methyl cellulose and transfection of primary keratinocytes has been described (Apt et al., 1996) . CAT reaction products were quantified with a PhosphorImager (Molecular Dynamics). This procedure determines in arbitrary units the CAT activity relative to the reference vector, p80 or pBLCAT3. Each value reported represents the average of the values of six independent transfections. The absence of AP-1 sites in some HPV types, e.g. HPV-2, which were later found to have strong enhancers may indicate that AP-1 can bind even more degenerate motifs. The E6 promoters of genital HPVs contain highly conserved Sp1 sites, which can diverge from the consensus motif GGGCGG by up to two nucleotides. The non-genital HPV types and the animal PVs of this figure do not have such a distinct motif at the promoter. Horizontal bars above the LCR of each HPV type indicate the genomic segment tested in this study, the letter ' e ' indicates an enhancer clone in the vector p80, the letters ' pe ' indicate an enhancer plus promoter clone in the vector pBLCAT3. Additional abbreviations in the case of BPV-1 (5h, C and 3h) indicate the respective subclones of the enhancer. Note that all HPV types in (A) are phylogenetically united in the supergroup of genital HPVs, while all PVs in (B) are -with the exception of HPV-5 and HPV-8 -unrelated to one another and unrelated to the genital HPVs. In the case of genital HPVs, enhancer clones were designed to exclude the two promoter-distal E2 binding sites and include all remaining nucleotides between these two sites. This very systematic cloning strategy had to be abandoned in the case of the non-genital PVs, as their E2, NFI and AP-1 sites were fairly evenly distributed throughout the LCR. Here, we cloned either a genome segment rich in NFI and AP-1 sites, or the complete LCR for enhancer tests.
Results

Most PVs have clusters of half-palindromic NFI motifs and AP-1 motifs
Epithelial specific enhancers have been characterized in HPV-11, HPV-16, HPV-18 and HPV-31. The organization of the LCRs of these four viruses is typical of the phylogenetic group of genital HPVs, as outlined in Fig. 1 (A) , with four binding sites for the viral transcription factor E2. Two of these are close to the E6 promoter and modulate this promoter together with the cellular Sp1 factor. Two further E2 sites lie about 100 bp and 500 bp, respectively, upstream of the promoter. These two sites serve as landmarks to divide the LCR into three segments with different and specific functions. The 5h LCR segment regulates transcription termination (Furth et al., 1994) and functions as a nuclear matrix attachment region (Tan et al., 1998) , the central segment contains the epithelial specific enhancer, and the 3h LCR segment contains the replication origin, the E6 promoter and silencer elements (Gloss & Bernard, 1990 ; Bauknecht et al., 1992 ; Lu et al., 1993 ; Kuo et al., 1994 ; Wang et al., 1996 ; O'Connor et al., 1998) .
The enhancers of the four studied genital HPVs are regulated by ten or more different transcription factors as identified through footprints, bandshifts and mutagenesis. Many factors target variable sequences that are difficult to identify by sequence analysis alone. Two of these factors, however, have highly conserved binding sites, namely AP-1, whose target TGANTCA does not vary by more than one nucleotide, and NFI, whose half-palindromic target is the conserved sequence TTGGC. Two or three AP-1 and five to seven NFI sites cluster over 200 bp to 350 bp in the centre of the LCRs of HPV-11, HPV-16, HPV-18 and HPV-31. As the enhancer coincides with this cluster, and mutations in AP-1 and NFI sites reduce enhancer activity, we assume that AP-1 and NFI site clusters in the central LCR segment of all genital HPV types can identify epithelial specific enhancers. Fig. 1 (A) summarizes the position of AP-1 and NFI motifs in the LCRs of seven different genital HPV types. It should be noted that HPV-2 and HPV-27 are phylogenetically classified as genital HPVs, although they cause common skin warts. As cutaneous and mucosal epithelia express different proteins, for example different cytokeratins (Quinlan et al., 1985) , one may assume that these two HPV types reside in a different transcriptional environment than the genital HPV types that infect the mucosa.
The structure of the LCRs of seven PVs that are unrelated to the genital HPVs is depicted in Fig. 1 (B) . Among these viruses HPV-5 and HPV-8 are related epidermodysplasia verruciformis PVs, which infect the skin, as do HPV-4 and HPV-1. BPV-1, BPV-4 and the Mastomys natalensis PV (MnPV) are distantly related to all HPVs and to one another (Chan et al., 1995) . The LCRs of these seven PVs differ significantly in size and in the number and position of E2 binding sites. The position of the E2 sites varies from those in genital HPVs, and does not suggest an organizational distinction of 5h, central and 3h LCR segments. In each of these PVs, one can identify half-palindromic NFI motifs and AP-1 sites. These sites are often close to one another, possibly reflecting functional linkage. All genital HPVs seem to have Sp1-activated promoters, while there are no clearly discernible Sp1 sites at the E6 promoters of other PVs.
Clusters of NFI and AP-1 motifs of PVs correlate with enhancers
Seven genital HPV types were included in this study in order to compare the known enhancers of HPV-11, HPV-16, HPV-18 and HPV-31 with one another under standardized conditions, and to test whether equivalent genomic segments of HPV-6, HPV-2 and HPV-27 would have similar activity in spite of the different pathology of the latter two viruses. To obtain standardized clones, we inserted LCR segments (' e ' segments in Fig. 1 A) between the two promoter-distal E2 sites into the test vector p80, including one (5h side) and two nucleotides (3h side), respectively, of the respective E2 binding sites. p80 contains the Sp1-activated promoter of HPV-16 (O'Connor et al., 1996) , which is homologous among all genital HPVs (Tan et al., 1994) and plays a role in the epithelial specific activation mechanism (Apt et al., 1996) . We refer to these clones as pHPV-Xe. Fig. 2 . Enhancer activity can be detected in the LCR of 14 different PV types, but shows major quantitative differences. Reporter vectors (10 µg) were electroporated into HeLa cells, and after 48 h the CAT activity in the lysate was determined and quantified with a PhosphorImager and is represented as a multiple of the activity observed for the promoter vector p80. The LCRs of the genital HPV types, HPV-2a, HPV-6, HPV-11, HPV-16, HPV-18 and HPV-31, and of BPV-1, showed 100-to more than 1000-fold enhancer activity. Lower activities (10-to 100-fold) were observed for the genital HPV type HPV-27, for BPV-4 and for MnPV. Very little activity (3-to 5-fold) was detected for HPV-4 and HPV-5, and for one of two subclones of HPV-1 and HPV-8. The activity of BPV-1 is restricted to the 5h-most third of the LCR.
It is not known which factor activates the promoters of PVs other than the genital HPVs. For seven non-genital PV types, we cloned LCR segments with clusters of NFI and AP-1 (' e ' segments in Fig. 1 B) into p80, and refer to these clones as above as pHPV-Xe. To avoid the possibility that one may miss an enhancer lacking NFI and AP-1 sites, we also cloned the complete LCR (' pe ' segments in Fig. 1 B) for HPV-1, HPV-8, BPV-1 and BPV-4, and refer to these clones as pHPV-XLe and pBPV-1Le. Table 1 summarizes positional details of these clones.
The activity of p80 is stimulated by the LCR fragments of all genital HPV types in HeLa cells from about 30-fold in the case of HPV-27 to more than 1000-fold for HPV-18, HPV-6 and HPV-11 (Fig. 2) . The transcriptional activity of most of these constructs exceeds that of the SV40 promoter and enhancer in pSV2CAT. Among the genital HPV types, the three strongest enhancers are found in HPV-6, HPV-11 and HPV-18, and the two weakest in HPV-16 and HPV-27. Under the conditions of this experiment, there is no clear correlation between enhancer strength and the biology of these HPVs. HPV-2a, HPV-6 and HPV-11, which are associated with cutaneous and genital warts, have stronger enhancers than the carcinoma-associated HPV-16, and HPV-16 and HPV-18 have enhancer activities differing by a factor of ten, although their ability to transform cells is similar. Enhancer activity was not detected in constructs containing the whole LCR of HPV-1 and HPV-8 (pHPV-1Le and pHPV-8Le in Fig. 2) , while short subclones of the LCRs containing NFI and AP-1 binding sites (pHPV-1e and pHPV-8e) demonstrated small but detectable activities similar to those exhibited by HPV-4 and HPV-5 LCR clones.
The only animal PV type with an enhancer of similar strength to that of the genital HPVs is BPV-1. The subcloning of the BPV-1 LCR into three segments localized this activity to a short stretch in the 5h portion of the LCR (clone pBPV-1 5h in Figs 1 and 2) at a different position from that of all genital HPVs, but overlapping with the location of enhancer activity described previously (van de Pol & Howley, 1990 , with little activity elsewhere in the LCR (clones pBPV-1 C and pBPV-1 3h). The active segment contains NFI as well as AP-1 binding motifs, which are absent from the other two fragments. Also, the complete LCR of BPV-4 with presumed NFI sites and the MnPV construct with AP-1 and NFI motifs show significant enhancer activity and stimulate transcription about 20-fold.
The enhancers of genital HPVs are specific for epithelial cells
The enhancers of HPV-11, HPV-16, HPV-18 and HPV-31 have been termed epithelial or keratinocyte specific as they are active in cell lines derived from cervical carcinomas as well as in continuously cultured skin cell lines. There is no detectable activity of these enhancers in a variety of other cell types, with fibroblasts normally serving as a control for the absence of activity (Cripe et al., 1987 ; Gloss et al., 1987 ; Chong et al., 1991 ; Dollard et al., 1993 ; Butz & Hoppe-Seyler, 1993 ; Kyo et al., 1995) .
To address the question of epithelial specificity, we compared the enhancers of ten PV types in HeLa, HaCat and MRHF, human cell lines derived from a cervical adenocarcinoma, skin and mesenchyme, respectively, as well as in undifferentiated and differentiated primary keratinocytes.
In HeLa cells, the enhancers of HPV-2a, HPV-6\11, HPV-16, HPV-18 and BPV-1 stimulated the p80 promoter 100-to more than 1000-fold, while weak activity of 2-to 12-fold was found with the LCRs of HPV-1, HPV-4, HPV-5\8 and BPV-4 (Figs 2 and 3 A, D) .
In HaCat cells, strong enhancer activity was observed for HPV-6\11, HPV-16, HPV-18 and BPV-1, while the enhancers of HPV-5 and HPV-8 demonstrated low activity, and nearly no stimulation was observed by HPV-1, HPV-2a and BPV-4 LCR sequences (Fig. 3 B) . This is surprising, as the latter viruses normally reside in cutaneous cells, whose transcriptional environment is modelled in vitro by HaCat cells. The much lower stimulation by the enhancers in HaCat cells as compared to HeLa cells may stem from the high basal activity of the p80 test vector due to the much higher Sp1 concentration in these cells (Apt et al., 1996) .
In the transcriptional environment of MRHF fibroblasts, transcription of pSV2CAT is impeded little, while very little Relative CAT activity Relative CAT activity p80 pSV2CAT pHPV-16 e pHPV-18 e pHPV-6/11 e pHPV-2a e pHPV-5/8 e pHPV-1 e pBPV-4 e p80 pSV2CAT pBPV-1 Le pBPV-1 5′ pBPV-1 c pBPV-1 3′ activity can be detected for any HPV enhancer (Fig. 3 C) . Surprisingly, the BPV-1 enhancer shows significant activity in fibroblasts, which localizes to the 5h portion of the LCR, similar to the enhancer activity in epithelial cells (Fig. 3 D-F) . This confirms the previous observation that this enhancer is not epithelial specific (van de Pol & Howley, 1990) , but is in contrast to the finding by the same researchers that activity is restricted to bovine cells.
Contiguous enhancer-promoter segments have significantly weaker activities than chimeric clones
Historically, the strong enhancers of genital HPVs have been studied in the form of chimeric test vectors, comprised of genomic segments cloned in front of homologous and heterologous promoters. This was necessary to ensure that these regions would fulfil the definition of an enhancer and was a prerequisite to manipulate individual transcription factor binding sites. It is evident, however, that the contiguous enhancer-promoter segment of HPV-16 is a much weaker transcriptional unit than chimeric constructs of the HPV-16 enhancer and homologous and heterologous promoters (Gloss et al., 1987) . This observation was explained by the detection of silencers, i.e. cis-responsive elements that bind repressors such as the transcription factor YY1 (Bauknecht et al., 1992 ; May et al., 1994 ; O'Connor et al., 1996 ; Wang et al., 1996) . Such silencers may be HPV type specific, as demonstrated by the mutual swapping of HPV-16 and HPV-18 promoter segments (Romanczuk et al., 1991) . Repression is particularly strong through the action of a novel silencer that overlaps with the replication origin and may be present in all PVs (O'Connor et al., 1998) .
To obtain a more complete understanding of these phenomena, we cloned the contiguous enhancer-promoter segments of eight PV types in front of the CAT gene of the vector pBLCAT3 in such a manner that CAT transcription was dependent only on the PV enhancer and its homologous promoter, and transfected these constructs into HeLa, HaCat and MRHF cells. Fig. 4 (A) shows that in HeLa cells, the LCR-promoter sequences of HPV-11 and HPV-18 stimulate CAT transcription to levels nearly reaching the positive control pSV2CAT. Expression from the LCR-promoter constructs of HPV-16, HPV-2a and BPV-1 is drastically reduced in comparison to the observations documented in Figs 2 and 3. The activity detected for HPV-1, HPV-8 and BPV-4 was negligible. These data indicate the presence of strong silencer elements in all of these viruses, as even the CAT levels observed with the most active viruses are more than an order of magnitude lower relative to pSV2CAT than the corresponding chimeric constructs.
Results depicted in Fig. 4 (B) indicate that this repression may be cell type specific, as in HaCat cells the LCR-promoter sequences of HPV-16 and HPV-2a boost CAT expression to approximately 20-fold background levels. As in HeLa cells, HPV-11 and HPV-18 have the highest activity, and weak or no stimulation of CAT expression is achieved with the LCRpromoters of the other four PV types. The combined promoter-enhancer activities are epithelial specific, as no CAT expression was observed in fibroblasts (Fig. 4 C) .
The transcriptional activities of all PVs in primary keratinocytes resemble those observed in HaCat, with the exception of the significant activation by the HPV-11 LCR. Transcription was generally higher in undifferentiated cells than in those after differentiation (Fig. 4 D, E) .
Discussion
Transcriptional properties of PVs correlate with phylogenetic relationship but not with target cell type or pathology
One of the objectives of this study was to examine whether epithelial specific enhancers occur in all PVs. There is good reason to assume that this could be the case, as most PVs replicate exclusively in epithelial cells, and transcriptional specificity rather than restricted infectivity seems to be the explanation for this limited host cell range. One of our strategies involved the use of artificially assembled transcription control units, LCR clones linked to the Sp1-activated E6 promoter of HPV-16. The two reasons for this were that (i) for many of the viruses studied neither the exact promoter position nor the factors activating the E6 promoters are known, and (ii) previous observations (Gloss et al., 1987 ; Romanczuk et al., 1991 ; Bauknecht et al., 1992 ; May et al., 1994 ; Wang et al., 1994 ; O'Connor et al., 1996 O'Connor et al., , 1998 indicated that PVs contain silencers that can conceal enhancer activity.
We learned from the initial part of our study that all genital HPVs, including those that target the skin (HPV-2a, HPV-27) rather than mucosal epithelia as well as those that normally cause benign neoplasia (HPV-2a, HPV-6, HPV-11, HPV-27) rather than malignancies, have strong and epithelial specific enhancers. All other HPVs studied, BPV-4 and MnPV have weak enhancers. This quantitative discrepancy is surprising as some of the genital and non-genital HPVs (HPV-2a and HPV-27 versus HPV-1, HPV-4, HPV-5 and HPV-8) infect the same type of skin cells and produce lesions of somewhat similar pathology.
Combinations of AP-1, NFI and Sp1 sites are alone insufficient for strong enhancer activation
The LCRs of HPV-11, HPV-16, HPV-18 and HPV-31 have similar cis-responsive elements, namely binding sites for E1, E2, Sp1 and TFIID close to the E6 promoter, and in the enhancer segment binding sites for AP-1, Oct-1, YY1 and steroid receptors. In addition, these enhancers have conspicuous sequence elements with lengths of about 30 bp and 15 bp, respectively, that are conserved among all genital HPVs (Swift et al., 1987 ; Myers et al., 1997) . These elements bind TEF-1 (Ishiji et al., 1992) , TEF-2 (Chong et al., 1991) and an Oct-1-NFI complex (O'Connor et al., 1996) . The recent detection of likely novel transcription factor binding sites by in vivo footprinting experiments may identify additional important factors (Bednarek et al., 1998) . Binding sites for additional proteins have been suggested to be specific for individual HPV types (Mack & Laimins, 1991 ; Kyo et al., 1995 ; Sibbet et al., 1995) .
The available evidence does not support the view that epithelial specificity originates from a single or a small number of epithelial transcription factors. An exception, skn-1, activates HPV-1, but in HPV-18 binds a sequence outside of the epithelial specific enhancer, and does not seem to bind other HPV enhancers (Yukawa et al., 1996 ; Andersen et al., 1997) . Mutations in all cis-responsive elements of HPVs interfere with transcription function, suggesting epithelial specific contributions of many of these factors. We have concentrated here on three of these numerous transcription factors, AP-1, NFI and Sp1, because (i) binding sites for these three factors can be recognized fairly reliably by nucleotide sequence inspection, and (ii) these three factors and TEF-1 are the only ones for which functional differences between epithelial and nonepithelial cells or between different layers of epithelia have been reported (Ishiji et al., 1992 ; Thierry et al., 1992 ; Offord et al., 1993 ; Apt et al., 1994 Apt et al., , 1996 Welter & Eckert, 1995 ; Kyo et al., 1997) .
This study does not resolve but rather complicates the synergistic model for HPV enhancer activation. Firstly, we observed strong enhancer activity in HPV-2a and HPV-27, although the nucleotide sequences of these two viruses suggest the absence of strong AP-1 binding sites. Secondly, we observed low enhancer activity in HPV-5 and HPV-8, although these viruses have strong NFI and AP-1 sites (Gloss et al., 1989 b) . The E6 promoters of HPV-5 and HPV-8, as in all nongenital HPV types, lack unequivocal Sp1 motifs, and the complementation of their NFI\AP-1 clusters by an Sp1-driven promoter resulted in only moderate activity and suggests unidentified elements that are absent from this chimeric construct. Thirdly, we observed high activity of the BPV-1 enhancer in epithelial cells as well as in fibroblasts, although BPV-1 has multiple NFI and AP-1 motifs, the typical hallmarks of epithelial specific HPV enhancers, and although some of our test vectors included an Sp1-activated promoter.
Cell type specific and HPV type specific silencing of transcription E6 transcription from the contiguous HPV-16 LCRpromoter clone is low when compared to chimeric constructs. Swaps between enhancers and promoters of HPV-16 and HPV-18 and dissection of these segments suggested silencers that depend on factor YY1 (Romanczuk et al., 1991 ; Bauknecht et al., 1992 ; May et al., 1994 ; O'Connor et al., 1996) and on a novel repressor (O'Connor et al., 1998) . Our observations suggest that these repression mechanisms may be cell type specific : in HeLa cells, the activities of the HPV-2a and HPV-16 enhancers are strongly repressed and those of HPV-11 and HPV-18 slightly repressed by these silencers, while these differences are much less pronounced in HaCat cells. Since both cell lines are not an optimal model for the natural environment of these viruses, we included undifferentiated and differentiated primary keratinocytes in this analysis. Independent of the differentiation state, the transcriptional environment of these cell lines repressed the transcription units of most PVs strongly, with moderate repression observed only in the case of HPV-11. Our observations are in line with those of other groups, as low transcriptional activity and correlations between transcription of HPVs and epithelial differentiation markers in cell culture and epithelial raft culture have been previously observed (Meyers et al., 1992 ; Cheng et al., 1995 ; Parker et al., 1997 ; Tergaonkar et al., 1997 ; Zhao et al., 1997) . Low transcriptional activities of PVs observed in this study should not be regarded as an unexpected finding, as the persistence of PV genomes in small populations of slowly growing cells would be incompatible with high levels of viral oncogene expression.
